Early circulating tumor DNA (ctDNA) changes predict survival in mismatch repair or microsatellite instability–high (dMMR/MSI-H) metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICIs).
Initiating fecal immunochemical test (FIT) screening before age 50 can significantly reduce colorectal cancer incidence and mortality, according to one study.
Structured exercise programs should be a part of the standard of care for colon cancer following adjuvant chemotherapy, authors of the CHALLENGE study recommended.
A circulating tumor DNA (ctDNA) blood test demonstrated high sensitivity and specificity for colorectal cancer (CRC) detection in a large average-risk population, study finds.
Fecal immunochemical testing (FIT) was more accurate than blood-based testing for detecting advanced precancerous colorectal lesions, a comparative study found.